{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:15:41Z","timestamp":1781496941725,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate the use of antibiotics in hospitals, to explore drug\u2010related problems (DRPs) linked to antibiotics and to introduce a novel way of expressing the risks accompanying use of various antibiotics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients from internal medicine departments in four Norwegian hospitals were prospectively included in 2002. Demographics, drugs used, medical history, laboratory data and clinical\/pharmacological risk factors were recorded. DRPs were identified by clinical pharmacists and assessed in multidisciplinary hospital teams. A new term, the drug risk ratio, was established and defined as the number of times the antibiotic was associated with DRPs in relation to the number of times it was used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of the 668 patients included, 283 patients (42%) used antibiotics (AB users). AB users were older (76.2 vs. 73.9), used more drugs on admission (5.1 vs. 4.4) and had more DRPs (3.0 vs. 2.2) than non\u2010users.<\/jats:p><jats:p>The DRP categories <jats:italic>no further need for drug, non\u2010optimal drug<\/jats:italic> and <jats:italic>non\u2010optimal dose<\/jats:italic> were most frequently observed. The drug risk ratio, calculated for 12 antibiotic groups, was highest for aminoglycosides (0.77), <jats:italic>\u03b2<\/jats:italic>\u2010lactamase\u2010resistant penicillins (0.56), macrolides (0.54) and quinolones (0.48) and lowest for first\u2010 and third\u2010generation cephalosporins, 0.17 and 0.13, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Nearly half of the hospitalised patients were prescribed antibiotics and antibiotic associated DRPs occurred frequently. The drug risk ratio for the different antibiotic groups varied with a factor of six from the lowest to the highest. A high drug risk ratio would alert of antibiotics which require heightened awareness when going to be used in clinical practice. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1595","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T16:47:43Z","timestamp":1207068463000},"page":"834-841","source":"Crossref","is-referenced-by-count":8,"title":["Risk of drug\u2010related problems for various antibiotics in hospital: assessment by use of a novel method"],"prefix":"10.1002","volume":"17","author":[{"given":"Hege Salvesen","family":"Blix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten K.","family":"Viktil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tron Anders","family":"Moger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasmund","family":"Reikvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0803.010192"},{"key":"e_1_2_1_3_2","first-page":"481","article-title":"Antibiotic misuse in medium\u2010sized Swiss hospitals","volume":"134","author":"Bugnon\u2010Reber A","year":"2004","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzg085"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.11.915.33630"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0501-2"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D182"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-002-0811-4"},{"key":"e_1_2_1_9_2","unstructured":"MDRD calculator. National Kidney Foundation2006. Available from:http:\/\/www.kidney.org\/professionals\/kdoqi\/gfr_calculator.cfm[17 March 2007]."},{"key":"e_1_2_1_10_2","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology.ATC Index with DDDs 2006. WHO Collaborating Centre: Oslo;2005."},{"key":"e_1_2_1_11_2","unstructured":"[Norsk Legemiddelh\u00e5ndbok for helsepersonell]. Oslo: Foreningen for utgivelse av Norsk Legemiddelh\u00e5ndbok December 2006. Available from:http:\/\/www.legemiddelhandboka.no[11 April2007]."},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0830-4"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-006-9020-z"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809002401114"},{"key":"e_1_2_1_15_2","unstructured":"HanstenPD HornJR.Drug interactions. Analysis and Management. Facts and comparisons: St. Louis;2000."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2007.00893.x"},{"key":"e_1_2_1_17_2","unstructured":"[Bruk av antibiotika i sykehus]. Oslo: Statens helsetilsyn IK\u20102737 2001. Available from:http:\/\/www.helsetilsynet.no"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki275"},{"key":"e_1_2_1_19_2","unstructured":"RosdahlVK PedersenKB.The Copenhagen Recommendations. Report from the Invitational EU Conference on The Microbial Threat. Ministry of Health Ministry of Food Agriculture and Fisheries: Denmark;2002;1\u201352."},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540151060923"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh327"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1595","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T20:53:20Z","timestamp":1695934400000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1002\/pds.1595"],"URL":"https:\/\/doi.org\/10.1002\/pds.1595","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}